Global Engage is pleased to announce the TMB & Neoantigen Congress part of the five-strong Research & Technology Series of events. With 20 expert speakers presenting on novel targets and the potential of predictive biomarkers, this conference offers an insight into the latest in precision medicine for oncology.
One of the key advantages of immuno-oncology is the potential to offer targeted personalized care for patients. However, challenges remain in matching patients to the therapies that offer the greatest chance of success, limiting efficacy depending on individual circumstances and increasing costs. Thus technologies that can assist in guiding therapies are vital – a role filled by predicted biomarker and neoantigen research.
This conference will explore the latest research on the tumour mutation burden and its potential for demonstrating the viability of immunotherapeutic treatment, as well as the development of other predictive biomarkers. A dedicated session will also examine the growing potential of neoantigens as novel targets for precision medicine
The TMB & Neoantigen Congress is one of five co-located conferences exploring key areas in immuno-oncology. The Research & Technology Series will attract over 100 speakers and 350+ attendees. These interactive meetings provide the opportunity to keep up to date with the cutting edge of research and make connections with industry experts, researchers, investors and businesses.